Nilotinib

규격

641571-10-0CAS 번호

700-544-5EC 번호

4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamideIUPAC 명칭

C28H22F3N7O화학식

529.5 g/mol분자량

Nilotinib; 641571-10-0; AMN 107; AMN-107; nilotinibum; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; Danziten; NSC-747599; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; DTXSID5042663; F41401512X; CHEBI:52172; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; RefChem:58968; AMN 107 Base; DTXCID3022663; L01XE08; benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate; Tasigna; AMN107; Nilotinib (AMN-107); Nilotinib free base; MFCD09833716; C28H22F3N7O; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; CHEMBL255863; NSC747599; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide; 4-Methyl-N-[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzamide; 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; Nilotinib,AMN107,Tasigna;4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; SMR002544680; Nilotinib [USAN]; Nilotinib [USAN:INN:BAN]; Nilotinib?; HSDB 7842; UNII-F41401512X; 641571-10-0 (free base); Nilotinib (Standard); 3gp0; NILOTINIB [INN]; NILOTINIB [MI]; Nilotinib (USAN/INN); NILOTINIB [HSDB]; 1353151-22-0; NILOTINIB [VANDF]; NILOTINIB [MART.]; EC 700-544-5; NILOTINIB [USP-RS]; NILOTINIB [WHO-DD]; SCHEMBL7901; NILOTINIB [EMA EPAR]; MLS003915611; MLS006010160; Nilotinib - Bio-X trade mark; GTPL5697; orb1224371; orb1308331; orb3141255; SCHEMBL29366964; SCHEMBL29580067; GLXC-90226; HMS3244A13; HMS3244A14; HMS3244B13; HMS3295A23; HMS3654M07; HMS3748E11; HMS5079M05; EX-A8380; TAC35617; AC-647; BDBM50237710; EBC-11364; HY-10159R; MSK159953; NSC800804; s1033; AKOS005063561; CCG-264784; CS-0102; DB04868; FM10831; NSC 747599; NSC-800804; SB17315; SDCCGSBI-0634418.P004; NCGC00183285-01; NCGC00183285-03; NCGC00183285-04; NCGC00183285-09; NCGC00183285-12; NCGC00183285-15; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]benzamide; AS-16214; BN164654; HY-10159; N-(3-(3-(1H-Imidazolyl)propoxy)phenyl)-4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)benzamide; SY024415; N3346; NS00000665; SW218083-2; T1524; D08953; N-8207; AB01273978-01; AB01273978-02; AB01273978_03; EN300-7381984; F079266; Q412327; SR-01000931150; SR-01000931150-2; BRD-K81528515-001-04-7; BRD-K81528515-001-13-8; Z1741976994; 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI)동의어